BBIO earnings: real EPS beat/miss history, analyst consensus Buy, P/E -22.04. Updated 2026-07-23.
BridgeBio Pharma (BBIO) Research Hub
BridgeBio Pharma (BBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 72.44 USD (-4.78%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -22.04, market cap 16.09B. This hub links to the full technical, earnings and options research available for BBIO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 72.44 USD (-4.78%) |
| 52-week range | 66 USD – 93.42 USD |
| Trend regime | Range |
| 14-day RSI | 23.6 (Oversold) |
| Trailing P/E | -22.04 |
| Market cap | 16.09B |
| Dividend yield | 0.00% |
Available research for BBIO
Covered Call on BBIO: how it works, illustrative setup around the real 72.44 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BBIO: how it works, illustrative setup around the real 72.44 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BBIO: how it works, illustrative setup around the real 72.44 USD price, max profit/loss, breakeven and when to use it. Educational.
BBIO technical analysis: range, last 72.44 USD, RSI 23.6, 52w range 66 USD–93.42 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BBIO in?
BridgeBio Pharma (BBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BBIO in an uptrend or downtrend?
As of 2026-09-11, BBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BBIO's trailing P/E ratio?
BBIO's trailing P/E is -22.04, with a market cap of 16.09B. See the earnings research page for full valuation detail.